Assessment of Memantine Drug Levels in Blood Among Indian Patients with Brain Metastases Treated with Radiation Therapy

Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/04/066217

Enrollment

Registered

2024-04-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified

Interventions

Intervention1: 2 ml Blood is to be collected from patient for LC/MS assay to measure blood concentration to conduct therapeutic drug monitoring.: 2ml Blood sample will be collected from patients with

Eligibility

Inclusion criteria

Inclusion criteria: (a) patients who are on the Memantine arm of CTRI/2022/01/039599 Trial (b) Patients who are willing to participate in the study, and provide informed consent

Exclusion criteria

Exclusion criteria: (a) Patients who are on the placebo Arm of CTRI/2022/01/039599 Trial (b) Patients who are not willing to participate in the study, and provide informed consent

Design outcomes

Primary

Measure	Time frame
To determine the therapeutic drug concentration in Indian patients with different dosage scheduleTimepoint: 1 month	—

Secondary

Measure	Time frame
To determine the correlation serum memantine concentration with cognitive function preservation Timepoint: 1 month;2. To correlate the Toxicity profile with serum memantine concentration Timepoint: 1 month	—

Countries

India

Contacts

Public ContactAparna K C

Amrita Vishwa Vidyapeetham University

duttadeb07@gmail.com9884234290

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026